Tagged with Clinical Trials

Japan Writing in the September 2025 edition of DIA’s Global Forum magazine, Seiko Usami, Shinichi Noda, Daisuke Koga, and Naoyuki Yasuda of the Pharmaceuticals and Medical Devices Agency (PMDA), Japan’s regulatory body, outline the benefits for global pharma of including Japan in their drug development activities.   Japan is one of…

USA Marwan Fathallah, President and CEO of DIA, outlines how the organisation has evolved into a neutral platform bringing together regulators, industry, and academia to navigate the most pressing issues in healthcare and life sciences. From the transformative potential of AI to the realities of drug pricing, onshoring, and global competition,…

China Dr Ben Zhao, Chief Executive Officer and co-founder of Haichang Biotechnology (HCBio, Haichang), represents a new paradigm in pharmaceutical innovation, bridging regulatory expertise with entrepreneurial vision. Having transitioned from a distinguished career at the FDA to establishing one of the most promising lipid nanoparticle delivery platforms in the industry, he…

Puerto Rico Long celebrated for its world-class pharmaceutical and medical device manufacturing, Puerto Rico is now leveraging this strong foundation to nurture a new era of research and development. Rather than shifting away from production, the island is integrating R&D directly into its manufacturing operations — from pilot plants and small-scale prototyping…

Brazil Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect of the organisation’s strategic transformation. His tenure spans critical periods of regulatory modernisation, digital transformation, and international collaboration, positioning him…

Denmark As clinical trials increasingly drift toward Asia and the US, can Denmark offer a blueprint for revitalising Europe’s competitive edge?   As Europe’s leader in clinical trials per capita, Denmark combines a deep domestic commitment to cutting-edge research with strong international confidence as a destination for investment. In 2023, the…

Europe As China and the US attract an increasing share of commercial clinical trials, Europe is fighting to reclaim its spot as a global research leader. While Europe has world-class hospitals and experienced regulators, it has struggled with a complicated and fragmented approval system that has pushed trial sponsors elsewhere. To…

Spain Dr Arcadi Navarro is a leading figure in modern Alzheimer’s research, heading efforts at the Pasqual Maragall Foundation in Barcelona and its university partners. His work spans genomics, bioinformatics, neurotropic viruses, and personalised brain organoids. Under his leadership, the foundation has doubled its research capacity and become a key player…

Denmark As Denmark and Europe enter a pivotal phase for healthcare and life sciences, Søren Granhøj Pedersen, Managing Director of MSD Denmark & Iceland, offers timely insights into how one of the world’s leading pharmaceutical companies is adapting and contributing. Drawing on a career shaped by international experience and cross-functional leadership,…

Denmark Helle Harder positions the Danish National Research Ethics Centre as a model for strategic regulatory innovation, aiming to boost Europe’s clinical trial competitiveness. By advancing AI integration, risk-based assessments, and cross-border harmonisation, Denmark is redefining ethical oversight. The Centre’s leadership articulates a compelling vision where regulatory excellence becomes a catalyst…

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

Denmark Marianne Pilgaard discusses the evolution of Denmark’s clinical trial landscape, the continued top-tier status of the country in trial activity per capita, and the nation’s commitment to digital innovation and patient-centric research. Pilgaard covers the impact of healthcare reform, regulatory harmonisation, decentralised trials, and the prospects for advanced therapies and…